Related Experiment Video
Updated: Jun 6, 2026
08:50
Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
Published on: January 9, 2026
Method for in vitro analysis of nanoparticle thrombogenic properties
Barry W Neun1, Marina A Dobrovolskaia
1Nanotechnology Characterization Laboratory, Advanced Technology Program, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD, USA.
Methods in Molecular Biology (Clifton, N.J.)
|December 1, 2010
Summary
This study details in vitro methods to assess nanomaterial thrombogenicity by measuring platelet aggregation and plasma coagulation. These tests help predict a material
Area of Science:
- Biomaterials Science
- Nanotechnology
- Hematology
Background:
- Thrombus formation is a complex process involving platelets and plasma proteins.
- Undesirable blood clot formation can lead to severe conditions like stroke.
- Thrombogenicity, the ability of a material to induce thrombus formation, is a critical safety concern for nanomaterials.
Purpose of the Study:
- To describe a standardized in vitro procedure for evaluating nanomaterial thrombogenicity.
- To assess the impact of nanoparticles on platelet aggregation and plasma coagulation.
- To provide a method for predicting in vivo thrombogenic potential based on in vitro assays.
Main Methods:
- Human whole blood is used to obtain platelet-rich plasma (PRP) and platelet-poor plasma.
- Nanoparticles are incubated with PRP, and platelet activation is quantified using a particle count and size analyzer.
- Plasma coagulation time is measured using prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time assays.
Main Results:
- The procedure allows for the calculation of percent platelet aggregation upon nanoparticle exposure.
- Plasma coagulation assays provide data on how nanoparticles affect the clotting cascade.
- These in vitro results serve as indicators of potential in vivo thrombogenicity.
Conclusions:
- In vitro assessment of platelet aggregation and plasma coagulation is a viable method to evaluate nanomaterial thrombogenicity.
- This standardized procedure can help predict the risk of blood clot formation associated with nanomaterial use.
- Accurate thrombogenicity testing is essential for the safe development and application of nanomaterials in biomedical fields.
